← Back to Search

Nonsteroidal Anti-inflammatory Drug (NSAID)

Cambia for Migraine

Phase 4
Waitlist Available
Led By Emily Rubenstein Engel, MD
Research Sponsored by Scripps Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention
Awards & highlights

Study Summary

This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.

Eligible Conditions
  • Migraine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain free response, 0-3 scale
Pain relief, 0-3 scale
Sustained pain free response, 0-3 scale
Secondary outcome measures
Change in severity of migraine associated symptoms
Return to function

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CambiaExperimental Treatment1 Intervention
Diclofenac postassium powder for oral solution and placebo injection
Group II: ketorolacActive Control1 Intervention
ketorolac intramuscular injection and placebo oral solution

Find a Location

Who is running the clinical trial?

Scripps HealthLead Sponsor
54 Previous Clinical Trials
11,752 Total Patients Enrolled
1 Trials studying Migraine
60 Patients Enrolled for Migraine
DepomedIndustry Sponsor
20 Previous Clinical Trials
3,540 Total Patients Enrolled
1 Trials studying Migraine
25 Patients Enrolled for Migraine
Emily Rubenstein Engel, MDPrincipal InvestigatorScripps Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Headache: The Journal of Head and Face PainJournal
The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies
Marmura, Michael J., Stephen D. Silberstein, and Todd J. Schwedt. 2015. “The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies”. Headache: The Journal of Head and Face Pain. Wiley. doi:10.1111/head.12499.
clinicaltrials.govStudy
IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine
Emily Rubenstein Engel 2016. "IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02664116.
All > Migraine
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top